カテゴリー： 世界, 医療/バイオ, LP Information

世界の切迫性尿失禁用治療薬市場予測 2023年-2029年

【英語タイトル】Global Medicines for Urge Incontinence Market Growth 2023-2029

LP Informationが出版した調査資料（LP23DC04489）・商品コード：LP23DC04489
・発行会社（調査会社）：LP Information
・発行日：2023年11月
・ページ数：105
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後2-3営業日）
・調査対象地域：グローバル、日本、アメリカ、ヨーロッパ、アジア、中国など
・産業分野：医薬品＆医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,660 ⇒換算￥556,320見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD5,490 ⇒換算￥834,480見積依頼/購入/質問フォーム
Corporate User（閲覧人数制限なし）USD7,320 ⇒換算￥1,112,640見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
❖ レポートの概要 ❖

LPインフォメーションの最新刊調査レポート「世界の切迫性尿失禁用治療薬市場」は、過去の販売実績から2022年の世界の切迫性尿失禁用治療薬の総販売量を検討し、2023年から2029年の予測される切迫性尿失禁用治療薬の販売量を地域別・市場分野別に包括的に分析しています。本調査レポートでは、地域別、市場分野別、サブセクター別の切迫性尿失禁用治療薬の市場規模を掲載し、XXX百万米ドル規模の世界の切迫性尿失禁用治療薬市場の詳細な分析を提供します。本インサイトレポートは、世界の切迫性尿失禁用治療薬業界を包括的に分析し、製品セグメント、企業情報、売上、市場シェア、最新動向、M&A活動に関する主要トレンドを明らかにしています。
また、本レポートでは、加速する世界の切迫性尿失禁用治療薬市場における各社の独自のポジションをより深く理解するために、切迫性尿失禁用治療薬製品ポートフォリオ、能力、市場参入戦略、市場でのポジション、海外展開に焦点を当て、主要なグローバル企業の戦略を分析しています。

世界の切迫性尿失禁用治療薬市場規模は、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに成長すると予測され、2023年から2029年までの年平均成長率は000%と予測されます。切迫性尿失禁用治療薬の米国市場は、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに増加し、2023年から2029年までのCAGRは000％と予測されています。切迫性尿失禁用治療薬の中国市場は、2023年から2029年までの年平均000％成長率で、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに増加すると推定されます。切迫性尿失禁用治療薬のヨーロッパ市場は、2023年から2029年にかけて年平均000％成長率で、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに増加すると推定されています。

切迫性尿失禁用治療薬の世界主要メーカーとしては、Pfizer、 Johnson & Johnson、 Merck、 Novartis、 GlaxoSmithKline、 Astellas Pharma、 Teva Pharmaceutical、 Mylan、 AbbVie、 Sanofiなどを掲載しており、売上の面では、世界の2大企業が2022年にほぼ000％のシェアを占めています。

本レポートでは、製品タイプ、用途、主要メーカー、主要地域、国別の切迫性尿失禁用治療薬市場の包括的な概要、市場シェア、成長機会などの情報を提供しています。

【市場細分化】

この調査では切迫性尿失禁用治療薬市場をセグメンテーションし、種類別 (抗コリン薬、β3刺激薬、その他)、用途別 (病院、診療所、その他)、および地域別 (アジア太平洋、南北アメリカ、ヨーロッパ、および中東・アフリカ) の市場規模を予測しています。

・種類別区分：抗コリン薬、β3刺激薬、その他

・用途別区分：病院、診療所、その他

・地域別区分
南北アメリカ（アメリカ、カナダ、メキシコ、ブラジル）
アジア太平洋（中国、日本、韓国、東南アジア、インド、オーストラリア）
ヨーロッパ（ドイツ、フランス、イギリス、イタリア、ロシア）
中東・アフリカ（エジプト、南アフリカ、イスラエル、トルコ、GCC諸国）

【本レポートで扱う主な質問】

・世界の切迫性尿失禁用治療薬市場の10年間の市場状況・展望は？
・世界および地域別に見た切迫性尿失禁用治療薬市場成長の要因は何か？
・切迫性尿失禁用治療薬の市場機会はエンドマーケットの規模によってどのように変化するのか？
・切迫性尿失禁用治療薬のタイプ別、用途別の内訳は？
・新型コロナウイルス感染症とロシア・ウクライナ戦争の影響は？

********* 目次 *********

レポートの範囲
・市場の紹介
・分析対象期間
・調査の目的
・調査手法
・調査プロセスおよびデータソース
・経済指標
・通貨

エグゼクティブサマリー
・世界市場の概要：切迫性尿失禁用治療薬の年間販売量2018-2029、地域別現状・将来分析
・切迫性尿失禁用治療薬の種類別セグメント：抗コリン薬、β3刺激薬、その他
・切迫性尿失禁用治療薬の種類別販売量：2018-2023年の販売量、売上、市場シェア、販売価格
・切迫性尿失禁用治療薬の用途別セグメント：病院、診療所、その他
・切迫性尿失禁用治療薬の用途別販売量：2018-2023年の販売量、売上、市場シェア、販売価格

企業別世界の切迫性尿失禁用治療薬市場
・企業別のグローバル切迫性尿失禁用治療薬市場データ：2018-2023年の年間販売量、市場シェア
・企業別の切迫性尿失禁用治療薬の年間売上：2018-2023年の売上、市場シェア
・企業別の切迫性尿失禁用治療薬販売価格
・主要企業の切迫性尿失禁用治療薬生産地域、販売地域、製品タイプ
・市場集中度分析
・新製品および潜在的な参加者
・合併と買収、拡大

切迫性尿失禁用治療薬の地域別レビュー
・地域別の切迫性尿失禁用治療薬市場規模2018-2023：年間販売量、売上
・主要国別の切迫性尿失禁用治療薬市場規模2018-2023：年間販売量、売上
・南北アメリカの切迫性尿失禁用治療薬販売の成長
・アジア太平洋の切迫性尿失禁用治療薬販売の成長
・ヨーロッパの切迫性尿失禁用治療薬販売の成長
・中東・アフリカの切迫性尿失禁用治療薬販売の成長

南北アメリカ市場
・南北アメリカの国別の切迫性尿失禁用治療薬販売量、売上（2018-2023）
・南北アメリカの切迫性尿失禁用治療薬の種類別販売量
・南北アメリカの切迫性尿失禁用治療薬の用途別販売量
・アメリカ市場
・カナダ市場
・メキシコ市場
・ブラジル市場

アジア太平洋市場
・アジア太平洋の国別の切迫性尿失禁用治療薬販売量、売上（2018-2023）
・アジア太平洋の切迫性尿失禁用治療薬の種類別販売量
・アジア太平洋の切迫性尿失禁用治療薬の用途別販売量
・中国市場
・日本市場
・韓国市場
・東南アジア市場
・インド市場
・オーストラリア市場
・台湾市場

ヨーロッパ市場
・ヨーロッパの国別の切迫性尿失禁用治療薬販売量、売上（2018-2023）
・ヨーロッパの切迫性尿失禁用治療薬の種類別販売量
・ヨーロッパの切迫性尿失禁用治療薬の用途別販売量
・ドイツ市場
・フランス市場
・イギリス市場
・イタリア市場
・ロシア市場

中東・アフリカ市場
・中東・アフリカの国別の切迫性尿失禁用治療薬販売量、売上（2018-2023）
・中東・アフリカの切迫性尿失禁用治療薬の種類別販売量
・中東・アフリカの切迫性尿失禁用治療薬の用途別販売量
・エジプト市場
・南アフリカ市場
・イスラエル市場
・トルコ市場
・GCC諸国市場

市場の成長要因、課題、動向
・市場の成長要因および成長機会分析
・市場の課題およびリスク
・市場動向

製造コスト構造分析
・原材料とサプライヤー
・切迫性尿失禁用治療薬の製造コスト構造分析
・切迫性尿失禁用治療薬の製造プロセス分析
・切迫性尿失禁用治療薬の産業チェーン構造

マーケティング、販売業者および顧客
・販売チャンネル：直接販売チャンネル、間接販売チャンネル
・切迫性尿失禁用治療薬の主要なグローバル販売業者
・切迫性尿失禁用治療薬の主要なグローバル顧客

地域別の切迫性尿失禁用治療薬市場予測レビュー
・地域別の切迫性尿失禁用治療薬市場規模予測（2024-2029）
・南北アメリカの国別予測
・アジア太平洋の国別予測
・ヨーロッパの国別予測
・切迫性尿失禁用治療薬の種類別市場規模予測
・切迫性尿失禁用治療薬の用途別市場規模予測

主要企業分析
Pfizer、 Johnson & Johnson、 Merck、 Novartis、 GlaxoSmithKline、 Astellas Pharma、 Teva Pharmaceutical、 Mylan、 AbbVie、 Sanofi
・企業情報
・切迫性尿失禁用治療薬製品
・切迫性尿失禁用治療薬販売量、売上、価格、粗利益（2018-2023）
・主要ビジネス概要
・最新動向

調査結果および結論

The global Medicines for Urge Incontinence market size is projected to grow from US$ 45 million in 2022 to US$ 71 million in 2029; it is expected to grow at a CAGR of 6.7% from 2023 to 2029.
United States market for Medicines for Urge Incontinence is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Medicines for Urge Incontinence is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Medicines for Urge Incontinence is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Medicines for Urge Incontinence players cover Pfizer, Johnson & Johnson, Merck, Novartis, GlaxoSmithKline, Astellas Pharma, Teva Pharmaceutical, Mylan and AbbVie, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
Urge incontinence is a type of urinary incontinence that occurs when a person experiences a sudden and intense urge to urinate, which can lead to involuntary leakage of urine. There are several medications that can be used to treat urge incontinence.
LPI (LP Information)’ newest research report, the “Medicines for Urge Incontinence Industry Forecast” looks at past sales and reviews total world Medicines for Urge Incontinence sales in 2022, providing a comprehensive analysis by region and market sector of projected Medicines for Urge Incontinence sales for 2023 through 2029. With Medicines for Urge Incontinence sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Medicines for Urge Incontinence industry.
This Insight Report provides a comprehensive analysis of the global Medicines for Urge Incontinence landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Medicines for Urge Incontinence portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Medicines for Urge Incontinence market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Medicines for Urge Incontinence and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Medicines for Urge Incontinence.
This report presents a comprehensive overview, market shares, and growth opportunities of Medicines for Urge Incontinence market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Anticholinergics
Beta-3 Agonists
Other
Segmentation by application
Hospital
Clinic
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company’s coverage, product portfolio, its market penetration.
Pfizer
Johnson & Johnson
Merck
Novartis
GlaxoSmithKline
Astellas Pharma
Teva Pharmaceutical
Mylan
AbbVie
Sanofi
Key Questions Addressed in this Report
What is the 10-year outlook for the global Medicines for Urge Incontinence market?
What factors are driving Medicines for Urge Incontinence market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Medicines for Urge Incontinence market opportunities vary by end market size?
How does Medicines for Urge Incontinence break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?

❖ レポートの目次 ❖

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Medicines for Urge Incontinence Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Medicines for Urge Incontinence by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Medicines for Urge Incontinence by Country/Region, 2018, 2022 & 2029
2.2 Medicines for Urge Incontinence Segment by Type
2.2.1 Anticholinergics
2.2.2 Beta-3 Agonists
2.2.3 Other
2.3 Medicines for Urge Incontinence Sales by Type
2.3.1 Global Medicines for Urge Incontinence Sales Market Share by Type (2018-2023)
2.3.2 Global Medicines for Urge Incontinence Revenue and Market Share by Type (2018-2023)
2.3.3 Global Medicines for Urge Incontinence Sale Price by Type (2018-2023)
2.4 Medicines for Urge Incontinence Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 Other
2.5 Medicines for Urge Incontinence Sales by Application
2.5.1 Global Medicines for Urge Incontinence Sale Market Share by Application (2018-2023)
2.5.2 Global Medicines for Urge Incontinence Revenue and Market Share by Application (2018-2023)
2.5.3 Global Medicines for Urge Incontinence Sale Price by Application (2018-2023)
3 Global Medicines for Urge Incontinence by Company
3.1 Global Medicines for Urge Incontinence Breakdown Data by Company
3.1.1 Global Medicines for Urge Incontinence Annual Sales by Company (2018-2023)
3.1.2 Global Medicines for Urge Incontinence Sales Market Share by Company (2018-2023)
3.2 Global Medicines for Urge Incontinence Annual Revenue by Company (2018-2023)
3.2.1 Global Medicines for Urge Incontinence Revenue by Company (2018-2023)
3.2.2 Global Medicines for Urge Incontinence Revenue Market Share by Company (2018-2023)
3.3 Global Medicines for Urge Incontinence Sale Price by Company
3.4 Key Manufacturers Medicines for Urge Incontinence Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Medicines for Urge Incontinence Product Location Distribution
3.4.2 Players Medicines for Urge Incontinence Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Medicines for Urge Incontinence by Geographic Region
4.1 World Historic Medicines for Urge Incontinence Market Size by Geographic Region (2018-2023)
4.1.1 Global Medicines for Urge Incontinence Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Medicines for Urge Incontinence Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Medicines for Urge Incontinence Market Size by Country/Region (2018-2023)
4.2.1 Global Medicines for Urge Incontinence Annual Sales by Country/Region (2018-2023)
4.2.2 Global Medicines for Urge Incontinence Annual Revenue by Country/Region (2018-2023)
4.3 Americas Medicines for Urge Incontinence Sales Growth
4.4 APAC Medicines for Urge Incontinence Sales Growth
4.5 Europe Medicines for Urge Incontinence Sales Growth
4.6 Middle East & Africa Medicines for Urge Incontinence Sales Growth
5 Americas
5.1 Americas Medicines for Urge Incontinence Sales by Country
5.1.1 Americas Medicines for Urge Incontinence Sales by Country (2018-2023)
5.1.2 Americas Medicines for Urge Incontinence Revenue by Country (2018-2023)
5.2 Americas Medicines for Urge Incontinence Sales by Type
5.3 Americas Medicines for Urge Incontinence Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Medicines for Urge Incontinence Sales by Region
6.1.1 APAC Medicines for Urge Incontinence Sales by Region (2018-2023)
6.1.2 APAC Medicines for Urge Incontinence Revenue by Region (2018-2023)
6.2 APAC Medicines for Urge Incontinence Sales by Type
6.3 APAC Medicines for Urge Incontinence Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Medicines for Urge Incontinence by Country
7.1.1 Europe Medicines for Urge Incontinence Sales by Country (2018-2023)
7.1.2 Europe Medicines for Urge Incontinence Revenue by Country (2018-2023)
7.2 Europe Medicines for Urge Incontinence Sales by Type
7.3 Europe Medicines for Urge Incontinence Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Medicines for Urge Incontinence by Country
8.1.1 Middle East & Africa Medicines for Urge Incontinence Sales by Country (2018-2023)
8.1.2 Middle East & Africa Medicines for Urge Incontinence Revenue by Country (2018-2023)
8.2 Middle East & Africa Medicines for Urge Incontinence Sales by Type
8.3 Middle East & Africa Medicines for Urge Incontinence Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Medicines for Urge Incontinence
10.3 Manufacturing Process Analysis of Medicines for Urge Incontinence
10.4 Industry Chain Structure of Medicines for Urge Incontinence
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Medicines for Urge Incontinence Distributors
11.3 Medicines for Urge Incontinence Customer
12 World Forecast Review for Medicines for Urge Incontinence by Geographic Region
12.1 Global Medicines for Urge Incontinence Market Size Forecast by Region
12.1.1 Global Medicines for Urge Incontinence Forecast by Region (2024-2029)
12.1.2 Global Medicines for Urge Incontinence Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Medicines for Urge Incontinence Forecast by Type
12.7 Global Medicines for Urge Incontinence Forecast by Application
13 Key Players Analysis
13.1 Pfizer
13.1.1 Pfizer Company Information
13.1.2 Pfizer Medicines for Urge Incontinence Product Portfolios and Specifications
13.1.3 Pfizer Medicines for Urge Incontinence Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Pfizer Main Business Overview
13.1.5 Pfizer Latest Developments
13.2 Johnson & Johnson
13.2.1 Johnson & Johnson Company Information
13.2.2 Johnson & Johnson Medicines for Urge Incontinence Product Portfolios and Specifications
13.2.3 Johnson & Johnson Medicines for Urge Incontinence Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Johnson & Johnson Main Business Overview
13.2.5 Johnson & Johnson Latest Developments
13.3 Merck
13.3.1 Merck Company Information
13.3.2 Merck Medicines for Urge Incontinence Product Portfolios and Specifications
13.3.3 Merck Medicines for Urge Incontinence Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Merck Main Business Overview
13.3.5 Merck Latest Developments
13.4 Novartis
13.4.1 Novartis Company Information
13.4.2 Novartis Medicines for Urge Incontinence Product Portfolios and Specifications
13.4.3 Novartis Medicines for Urge Incontinence Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Novartis Main Business Overview
13.4.5 Novartis Latest Developments
13.5 GlaxoSmithKline
13.5.1 GlaxoSmithKline Company Information
13.5.2 GlaxoSmithKline Medicines for Urge Incontinence Product Portfolios and Specifications
13.5.3 GlaxoSmithKline Medicines for Urge Incontinence Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 GlaxoSmithKline Main Business Overview
13.5.5 GlaxoSmithKline Latest Developments
13.6 Astellas Pharma
13.6.1 Astellas Pharma Company Information
13.6.2 Astellas Pharma Medicines for Urge Incontinence Product Portfolios and Specifications
13.6.3 Astellas Pharma Medicines for Urge Incontinence Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Astellas Pharma Main Business Overview
13.6.5 Astellas Pharma Latest Developments
13.7 Teva Pharmaceutical
13.7.1 Teva Pharmaceutical Company Information
13.7.2 Teva Pharmaceutical Medicines for Urge Incontinence Product Portfolios and Specifications
13.7.3 Teva Pharmaceutical Medicines for Urge Incontinence Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Teva Pharmaceutical Main Business Overview
13.7.5 Teva Pharmaceutical Latest Developments
13.8 Mylan
13.8.1 Mylan Company Information
13.8.2 Mylan Medicines for Urge Incontinence Product Portfolios and Specifications
13.8.3 Mylan Medicines for Urge Incontinence Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Mylan Main Business Overview
13.8.5 Mylan Latest Developments
13.9 AbbVie
13.9.1 AbbVie Company Information
13.9.2 AbbVie Medicines for Urge Incontinence Product Portfolios and Specifications
13.9.3 AbbVie Medicines for Urge Incontinence Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 AbbVie Main Business Overview
13.9.5 AbbVie Latest Developments
13.10 Sanofi
13.10.1 Sanofi Company Information
13.10.2 Sanofi Medicines for Urge Incontinence Product Portfolios and Specifications
13.10.3 Sanofi Medicines for Urge Incontinence Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Sanofi Main Business Overview
13.10.5 Sanofi Latest Developments
14 Research Findings and Conclusion

List of Tables
Table 1. Medicines for Urge Incontinence Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Medicines for Urge Incontinence Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Anticholinergics
Table 4. Major Players of Beta-3 Agonists
Table 5. Major Players of Other
Table 6. Global Medicines for Urge Incontinence Sales by Type (2018-2023) & (K Units)
Table 7. Global Medicines for Urge Incontinence Sales Market Share by Type (2018-2023)
Table 8. Global Medicines for Urge Incontinence Revenue by Type (2018-2023) & ($ million)
Table 9. Global Medicines for Urge Incontinence Revenue Market Share by Type (2018-2023)
Table 10. Global Medicines for Urge Incontinence Sale Price by Type (2018-2023) & (US$/Unit)
Table 11. Global Medicines for Urge Incontinence Sales by Application (2018-2023) & (K Units)
Table 12. Global Medicines for Urge Incontinence Sales Market Share by Application (2018-2023)
Table 13. Global Medicines for Urge Incontinence Revenue by Application (2018-2023)
Table 14. Global Medicines for Urge Incontinence Revenue Market Share by Application (2018-2023)
Table 15. Global Medicines for Urge Incontinence Sale Price by Application (2018-2023) & (US$/Unit)
Table 16. Global Medicines for Urge Incontinence Sales by Company (2018-2023) & (K Units)
Table 17. Global Medicines for Urge Incontinence Sales Market Share by Company (2018-2023)
Table 18. Global Medicines for Urge Incontinence Revenue by Company (2018-2023) ($ Millions)
Table 19. Global Medicines for Urge Incontinence Revenue Market Share by Company (2018-2023)
Table 20. Global Medicines for Urge Incontinence Sale Price by Company (2018-2023) & (US$/Unit)
Table 21. Key Manufacturers Medicines for Urge Incontinence Producing Area Distribution and Sales Area
Table 22. Players Medicines for Urge Incontinence Products Offered
Table 23. Medicines for Urge Incontinence Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 24. New Products and Potential Entrants
Table 25. Mergers & Acquisitions, Expansion
Table 26. Global Medicines for Urge Incontinence Sales by Geographic Region (2018-2023) & (K Units)
Table 27. Global Medicines for Urge Incontinence Sales Market Share Geographic Region (2018-2023)
Table 28. Global Medicines for Urge Incontinence Revenue by Geographic Region (2018-2023) & ($ millions)
Table 29. Global Medicines for Urge Incontinence Revenue Market Share by Geographic Region (2018-2023)
Table 30. Global Medicines for Urge Incontinence Sales by Country/Region (2018-2023) & (K Units)
Table 31. Global Medicines for Urge Incontinence Sales Market Share by Country/Region (2018-2023)
Table 32. Global Medicines for Urge Incontinence Revenue by Country/Region (2018-2023) & ($ millions)
Table 33. Global Medicines for Urge Incontinence Revenue Market Share by Country/Region (2018-2023)
Table 34. Americas Medicines for Urge Incontinence Sales by Country (2018-2023) & (K Units)
Table 35. Americas Medicines for Urge Incontinence Sales Market Share by Country (2018-2023)
Table 36. Americas Medicines for Urge Incontinence Revenue by Country (2018-2023) & ($ Millions)
Table 37. Americas Medicines for Urge Incontinence Revenue Market Share by Country (2018-2023)
Table 38. Americas Medicines for Urge Incontinence Sales by Type (2018-2023) & (K Units)
Table 39. Americas Medicines for Urge Incontinence Sales by Application (2018-2023) & (K Units)
Table 40. APAC Medicines for Urge Incontinence Sales by Region (2018-2023) & (K Units)
Table 41. APAC Medicines for Urge Incontinence Sales Market Share by Region (2018-2023)
Table 42. APAC Medicines for Urge Incontinence Revenue by Region (2018-2023) & ($ Millions)
Table 43. APAC Medicines for Urge Incontinence Revenue Market Share by Region (2018-2023)
Table 44. APAC Medicines for Urge Incontinence Sales by Type (2018-2023) & (K Units)
Table 45. APAC Medicines for Urge Incontinence Sales by Application (2018-2023) & (K Units)
Table 46. Europe Medicines for Urge Incontinence Sales by Country (2018-2023) & (K Units)
Table 47. Europe Medicines for Urge Incontinence Sales Market Share by Country (2018-2023)
Table 48. Europe Medicines for Urge Incontinence Revenue by Country (2018-2023) & ($ Millions)
Table 49. Europe Medicines for Urge Incontinence Revenue Market Share by Country (2018-2023)
Table 50. Europe Medicines for Urge Incontinence Sales by Type (2018-2023) & (K Units)
Table 51. Europe Medicines for Urge Incontinence Sales by Application (2018-2023) & (K Units)
Table 52. Middle East & Africa Medicines for Urge Incontinence Sales by Country (2018-2023) & (K Units)
Table 53. Middle East & Africa Medicines for Urge Incontinence Sales Market Share by Country (2018-2023)
Table 54. Middle East & Africa Medicines for Urge Incontinence Revenue by Country (2018-2023) & ($ Millions)
Table 55. Middle East & Africa Medicines for Urge Incontinence Revenue Market Share by Country (2018-2023)
Table 56. Middle East & Africa Medicines for Urge Incontinence Sales by Type (2018-2023) & (K Units)
Table 57. Middle East & Africa Medicines for Urge Incontinence Sales by Application (2018-2023) & (K Units)
Table 58. Key Market Drivers & Growth Opportunities of Medicines for Urge Incontinence
Table 59. Key Market Challenges & Risks of Medicines for Urge Incontinence
Table 60. Key Industry Trends of Medicines for Urge Incontinence
Table 61. Medicines for Urge Incontinence Raw Material
Table 62. Key Suppliers of Raw Materials
Table 63. Medicines for Urge Incontinence Distributors List
Table 64. Medicines for Urge Incontinence Customer List
Table 65. Global Medicines for Urge Incontinence Sales Forecast by Region (2024-2029) & (K Units)
Table 66. Global Medicines for Urge Incontinence Revenue Forecast by Region (2024-2029) & ($ millions)
Table 67. Americas Medicines for Urge Incontinence Sales Forecast by Country (2024-2029) & (K Units)
Table 68. Americas Medicines for Urge Incontinence Revenue Forecast by Country (2024-2029) & ($ millions)
Table 69. APAC Medicines for Urge Incontinence Sales Forecast by Region (2024-2029) & (K Units)
Table 70. APAC Medicines for Urge Incontinence Revenue Forecast by Region (2024-2029) & ($ millions)
Table 71. Europe Medicines for Urge Incontinence Sales Forecast by Country (2024-2029) & (K Units)
Table 72. Europe Medicines for Urge Incontinence Revenue Forecast by Country (2024-2029) & ($ millions)
Table 73. Middle East & Africa Medicines for Urge Incontinence Sales Forecast by Country (2024-2029) & (K Units)
Table 74. Middle East & Africa Medicines for Urge Incontinence Revenue Forecast by Country (2024-2029) & ($ millions)
Table 75. Global Medicines for Urge Incontinence Sales Forecast by Type (2024-2029) & (K Units)
Table 76. Global Medicines for Urge Incontinence Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 77. Global Medicines for Urge Incontinence Sales Forecast by Application (2024-2029) & (K Units)
Table 78. Global Medicines for Urge Incontinence Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 79. Pfizer Basic Information, Medicines for Urge Incontinence Manufacturing Base, Sales Area and Its Competitors
Table 80. Pfizer Medicines for Urge Incontinence Product Portfolios and Specifications
Table 81. Pfizer Medicines for Urge Incontinence Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 82. Pfizer Main Business
Table 83. Pfizer Latest Developments
Table 84. Johnson & Johnson Basic Information, Medicines for Urge Incontinence Manufacturing Base, Sales Area and Its Competitors
Table 85. Johnson & Johnson Medicines for Urge Incontinence Product Portfolios and Specifications
Table 86. Johnson & Johnson Medicines for Urge Incontinence Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 87. Johnson & Johnson Main Business
Table 88. Johnson & Johnson Latest Developments
Table 89. Merck Basic Information, Medicines for Urge Incontinence Manufacturing Base, Sales Area and Its Competitors
Table 90. Merck Medicines for Urge Incontinence Product Portfolios and Specifications
Table 91. Merck Medicines for Urge Incontinence Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 92. Merck Main Business
Table 93. Merck Latest Developments
Table 94. Novartis Basic Information, Medicines for Urge Incontinence Manufacturing Base, Sales Area and Its Competitors
Table 95. Novartis Medicines for Urge Incontinence Product Portfolios and Specifications
Table 96. Novartis Medicines for Urge Incontinence Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 97. Novartis Main Business
Table 98. Novartis Latest Developments
Table 99. GlaxoSmithKline Basic Information, Medicines for Urge Incontinence Manufacturing Base, Sales Area and Its Competitors
Table 100. GlaxoSmithKline Medicines for Urge Incontinence Product Portfolios and Specifications
Table 101. GlaxoSmithKline Medicines for Urge Incontinence Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 102. GlaxoSmithKline Main Business
Table 103. GlaxoSmithKline Latest Developments
Table 104. Astellas Pharma Basic Information, Medicines for Urge Incontinence Manufacturing Base, Sales Area and Its Competitors
Table 105. Astellas Pharma Medicines for Urge Incontinence Product Portfolios and Specifications
Table 106. Astellas Pharma Medicines for Urge Incontinence Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 107. Astellas Pharma Main Business
Table 108. Astellas Pharma Latest Developments
Table 109. Teva Pharmaceutical Basic Information, Medicines for Urge Incontinence Manufacturing Base, Sales Area and Its Competitors
Table 110. Teva Pharmaceutical Medicines for Urge Incontinence Product Portfolios and Specifications
Table 111. Teva Pharmaceutical Medicines for Urge Incontinence Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 112. Teva Pharmaceutical Main Business
Table 113. Teva Pharmaceutical Latest Developments
Table 114. Mylan Basic Information, Medicines for Urge Incontinence Manufacturing Base, Sales Area and Its Competitors
Table 115. Mylan Medicines for Urge Incontinence Product Portfolios and Specifications
Table 116. Mylan Medicines for Urge Incontinence Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 117. Mylan Main Business
Table 118. Mylan Latest Developments
Table 119. AbbVie Basic Information, Medicines for Urge Incontinence Manufacturing Base, Sales Area and Its Competitors
Table 120. AbbVie Medicines for Urge Incontinence Product Portfolios and Specifications
Table 121. AbbVie Medicines for Urge Incontinence Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 122. AbbVie Main Business
Table 123. AbbVie Latest Developments
Table 124. Sanofi Basic Information, Medicines for Urge Incontinence Manufacturing Base, Sales Area and Its Competitors
Table 125. Sanofi Medicines for Urge Incontinence Product Portfolios and Specifications
Table 126. Sanofi Medicines for Urge Incontinence Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 127. Sanofi Main Business
Table 128. Sanofi Latest Developments
List of Figures
Figure 1. Picture of Medicines for Urge Incontinence
Figure 2. Medicines for Urge Incontinence Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Medicines for Urge Incontinence Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global Medicines for Urge Incontinence Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Medicines for Urge Incontinence Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Anticholinergics
Figure 10. Product Picture of Beta-3 Agonists
Figure 11. Product Picture of Other
Figure 12. Global Medicines for Urge Incontinence Sales Market Share by Type in 2022
Figure 13. Global Medicines for Urge Incontinence Revenue Market Share by Type (2018-2023)
Figure 14. Medicines for Urge Incontinence Consumed in Hospital
Figure 15. Global Medicines for Urge Incontinence Market: Hospital (2018-2023) & (K Units)
Figure 16. Medicines for Urge Incontinence Consumed in Clinic
Figure 17. Global Medicines for Urge Incontinence Market: Clinic (2018-2023) & (K Units)
Figure 18. Medicines for Urge Incontinence Consumed in Other
Figure 19. Global Medicines for Urge Incontinence Market: Other (2018-2023) & (K Units)
Figure 20. Global Medicines for Urge Incontinence Sales Market Share by Application (2022)
Figure 21. Global Medicines for Urge Incontinence Revenue Market Share by Application in 2022
Figure 22. Medicines for Urge Incontinence Sales Market by Company in 2022 (K Units)
Figure 23. Global Medicines for Urge Incontinence Sales Market Share by Company in 2022
Figure 24. Medicines for Urge Incontinence Revenue Market by Company in 2022 ($ Million)
Figure 25. Global Medicines for Urge Incontinence Revenue Market Share by Company in 2022
Figure 26. Global Medicines for Urge Incontinence Sales Market Share by Geographic Region (2018-2023)
Figure 27. Global Medicines for Urge Incontinence Revenue Market Share by Geographic Region in 2022
Figure 28. Americas Medicines for Urge Incontinence Sales 2018-2023 (K Units)
Figure 29. Americas Medicines for Urge Incontinence Revenue 2018-2023 ($ Millions)
Figure 30. APAC Medicines for Urge Incontinence Sales 2018-2023 (K Units)
Figure 31. APAC Medicines for Urge Incontinence Revenue 2018-2023 ($ Millions)
Figure 32. Europe Medicines for Urge Incontinence Sales 2018-2023 (K Units)
Figure 33. Europe Medicines for Urge Incontinence Revenue 2018-2023 ($ Millions)
Figure 34. Middle East & Africa Medicines for Urge Incontinence Sales 2018-2023 (K Units)
Figure 35. Middle East & Africa Medicines for Urge Incontinence Revenue 2018-2023 ($ Millions)
Figure 36. Americas Medicines for Urge Incontinence Sales Market Share by Country in 2022
Figure 37. Americas Medicines for Urge Incontinence Revenue Market Share by Country in 2022
Figure 38. Americas Medicines for Urge Incontinence Sales Market Share by Type (2018-2023)
Figure 39. Americas Medicines for Urge Incontinence Sales Market Share by Application (2018-2023)
Figure 40. United States Medicines for Urge Incontinence Revenue Growth 2018-2023 ($ Millions)
Figure 41. Canada Medicines for Urge Incontinence Revenue Growth 2018-2023 ($ Millions)
Figure 42. Mexico Medicines for Urge Incontinence Revenue Growth 2018-2023 ($ Millions)
Figure 43. Brazil Medicines for Urge Incontinence Revenue Growth 2018-2023 ($ Millions)
Figure 44. APAC Medicines for Urge Incontinence Sales Market Share by Region in 2022
Figure 45. APAC Medicines for Urge Incontinence Revenue Market Share by Regions in 2022
Figure 46. APAC Medicines for Urge Incontinence Sales Market Share by Type (2018-2023)
Figure 47. APAC Medicines for Urge Incontinence Sales Market Share by Application (2018-2023)
Figure 48. China Medicines for Urge Incontinence Revenue Growth 2018-2023 ($ Millions)
Figure 49. Japan Medicines for Urge Incontinence Revenue Growth 2018-2023 ($ Millions)
Figure 50. South Korea Medicines for Urge Incontinence Revenue Growth 2018-2023 ($ Millions)
Figure 51. Southeast Asia Medicines for Urge Incontinence Revenue Growth 2018-2023 ($ Millions)
Figure 52. India Medicines for Urge Incontinence Revenue Growth 2018-2023 ($ Millions)
Figure 53. Australia Medicines for Urge Incontinence Revenue Growth 2018-2023 ($ Millions)
Figure 54. China Taiwan Medicines for Urge Incontinence Revenue Growth 2018-2023 ($ Millions)
Figure 55. Europe Medicines for Urge Incontinence Sales Market Share by Country in 2022
Figure 56. Europe Medicines for Urge Incontinence Revenue Market Share by Country in 2022
Figure 57. Europe Medicines for Urge Incontinence Sales Market Share by Type (2018-2023)
Figure 58. Europe Medicines for Urge Incontinence Sales Market Share by Application (2018-2023)
Figure 59. Germany Medicines for Urge Incontinence Revenue Growth 2018-2023 ($ Millions)
Figure 60. France Medicines for Urge Incontinence Revenue Growth 2018-2023 ($ Millions)
Figure 61. UK Medicines for Urge Incontinence Revenue Growth 2018-2023 ($ Millions)
Figure 62. Italy Medicines for Urge Incontinence Revenue Growth 2018-2023 ($ Millions)
Figure 63. Russia Medicines for Urge Incontinence Revenue Growth 2018-2023 ($ Millions)
Figure 64. Middle East & Africa Medicines for Urge Incontinence Sales Market Share by Country in 2022
Figure 65. Middle East & Africa Medicines for Urge Incontinence Revenue Market Share by Country in 2022
Figure 66. Middle East & Africa Medicines for Urge Incontinence Sales Market Share by Type (2018-2023)
Figure 67. Middle East & Africa Medicines for Urge Incontinence Sales Market Share by Application (2018-2023)
Figure 68. Egypt Medicines for Urge Incontinence Revenue Growth 2018-2023 ($ Millions)
Figure 69. South Africa Medicines for Urge Incontinence Revenue Growth 2018-2023 ($ Millions)
Figure 70. Israel Medicines for Urge Incontinence Revenue Growth 2018-2023 ($ Millions)
Figure 71. Turkey Medicines for Urge Incontinence Revenue Growth 2018-2023 ($ Millions)
Figure 72. GCC Country Medicines for Urge Incontinence Revenue Growth 2018-2023 ($ Millions)
Figure 73. Manufacturing Cost Structure Analysis of Medicines for Urge Incontinence in 2022
Figure 74. Manufacturing Process Analysis of Medicines for Urge Incontinence
Figure 75. Industry Chain Structure of Medicines for Urge Incontinence
Figure 76. Channels of Distribution
Figure 77. Global Medicines for Urge Incontinence Sales Market Forecast by Region (2024-2029)
Figure 78. Global Medicines for Urge Incontinence Revenue Market Share Forecast by Region (2024-2029)
Figure 79. Global Medicines for Urge Incontinence Sales Market Share Forecast by Type (2024-2029)
Figure 80. Global Medicines for Urge Incontinence Revenue Market Share Forecast by Type (2024-2029)
Figure 81. Global Medicines for Urge Incontinence Sales Market Share Forecast by Application (2024-2029)
Figure 82. Global Medicines for Urge Incontinence Revenue Market Share Forecast by Application (2024-2029)


★調査レポート[世界の切迫性尿失禁用治療薬市場予測 2023年-2029年] (コード：LP23DC04489)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の切迫性尿失禁用治療薬市場予測 2023年-2029年]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 世界の甲状腺乳頭がん治療市場予測 2023年-2029年
  • 世界のアジスロマイシン錠市場予測 2023年-2029年
  • 世界のアログリプチン安息香酸塩錠市場予測 2023年-2029年
  • 世界の寛骨臼メッシュ市場予測 2023年-2029年
  • 世界の整形外科用使い捨て製品市場予測 2023年-2029年

    • ◆H&Iグローバルリサーチのお客様（例）◆